References
Sun BL, Li WW, Zhu C, Jin WS, Zeng F, Liu YH, et al. Clinical research on Alzheimer’s disease: progress and perspectives. Neurosci Bull 2018, 34: 1111–1118.
Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985, 82: 4245–4249.
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 2016, 8: 595–608.
Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol 2019, 15: 73–88.
Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, et al. Randomized trial of verubecestat for prodromal Alzheimer’s disease. N Engl J Med 2019, 380: 1408–1420.
Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G. Preliminary results of a trial of atabecestat in preclinical Alzheimer’s disease. N Engl J Med 2019, 380: 1483–1485.
Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, et al. Control of peripheral nerve myelination by the beta-secretase BACE1. Science 2006, 314: 664–666.
Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S, et al. eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 2015, 526: 443–447.
Roberts BR, Lind M, Wagen AZ, Rembach A, Frugier T, Li QX, et al. Biochemically-defined pools of amyloid-beta in sporadic Alzheimer’s disease: correlation with amyloid PET. Brain 2017, 140: 1486–1498.
Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001, 81: 741–766.
Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 2012, 488: 96–99.
McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 2018, 91: e1295–e1306.
Bu XL, Jiao SS, Lian Y, Wang YJ. Perspectives on the tertiary prevention strategy for Alzheimer’s disease. Curr Alzheimer Res 2016, 13: 307–316.
Acknowledgements
This highlight was supported by the National Natural Science Foundation of China (91749206 and 81625007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interests.
Rights and permissions
About this article
Cite this article
Fan, DY., Wang, YJ. Early Intervention in Alzheimer’s Disease: How Early is Early Enough?. Neurosci. Bull. 36, 195–197 (2020). https://doi.org/10.1007/s12264-019-00429-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12264-019-00429-x